Ando Yuichi, Shimokata Tomoya, Yasuda Yoshinari, Hasegawa Yoshinori
Nagoya J Med Sci. 2014 Feb;76(1-2):1-9.
Carboplatin is a platinum-based anticancer drug that has been long used to treat many types of solid cancer. Because the clearance of carboplatin strongly correlates with the glomerular filtration rate (GFR), its dosage is calculated with the Calvert formula on the basis of the patient's GFR to achieve the target area under the plasma drug concentration-time curve (AUC) for each patient. However, many lines of evidence from previous clinical studies should be interpreted with caution because different methods were used to estimate drug clearance and derive the dosage of carboplatin. There is a particularly high risk of carboplatin overdosing when the dosage is determined on the basis of standardized serum creatinine values. When deciding the dose of carboplatin for adult Japanese patients, preferred methods to assess renal function instead of directly measuring GFR include (1) 24-h urinary collection-based creatinine clearance adjusted by adding 0.2 mg/dl to the serum creatinine concentration measured by standardized methods, and (2) equation-based GFR (eGFR) with a back calculation to units of ml/min per subject. Given the limitations of serum creatinine-based GFR estimations, the GFR or creatinine clearance should be directly measured in each patient whenever possible. To ensure patient safety and facilitate a medical-team approach, the single most appropriate method available at each institute or medical team should be consistently used to calculate the dose of carboplatin with the Calvert formula.
卡铂是一种铂类抗癌药物,长期以来一直用于治疗多种实体癌。由于卡铂的清除率与肾小球滤过率(GFR)密切相关,其剂量根据患者的GFR,采用卡尔弗特公式计算,以达到每位患者血浆药物浓度-时间曲线下的目标面积(AUC)。然而,以往临床研究的许多证据在解释时应谨慎,因为用于估计药物清除率和推导卡铂剂量的方法不同。当根据标准化血清肌酐值确定剂量时,卡铂过量的风险特别高。在为成年日本患者确定卡铂剂量时,评估肾功能的首选方法(而非直接测量GFR)包括:(1)基于24小时尿样收集的肌酐清除率,通过在标准化方法测量的血清肌酐浓度上加上0.2mg/dl进行调整;(2)基于公式的GFR(eGFR),并将结果换算为每位受试者每分钟毫升数的单位。鉴于基于血清肌酐的GFR估计存在局限性,应尽可能直接测量每位患者的GFR或肌酐清除率。为确保患者安全并促进医疗团队协作,各机构或医疗团队应始终使用最适合的单一方法,根据卡尔弗特公式计算卡铂剂量。